brain-penetrant LSD1 inh. for neuro. disorders

sociability improvement in vivo, completed Ph. I in HV

tranylcypromine class mechanism-based inh.

Sci. Adv., Mar. 12, 2021

Takeda Pharmaceuticals, Fujisawa, JP

Structure of TAK-418 (Takeda lysine-specific demethylase 1 inhibitor)

The Takeda lysine-specific demethylase 1 (LSD1) inhibitor (TAK-418) is an oral CNS-penetrant clinical candidate for neurodevelopmental disorders such as autism spectrum disorder. We previously highlighted irreversible and reversible LSD1…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: